US Patent

US8512717 — Compositions for delivery of therapeutics into the eyes and methods for making and using same

Formulation · Assigned to Allergan Inc · Expires 2028-03-07 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions for delivering therapeutics into the eyes, including a carrier, therapeutic component, and retention component to improve retention on the cornea.

USPTO Abstract

The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.

Drugs covered by this patent

Patent Metadata

Patent number
US8512717
Jurisdiction
US
Classification
Formulation
Expires
2028-03-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.